Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder
PLoS One May 7, 2025 DOI: 10.1371/journal.pone.0321461 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cross-sectional survey analysis Longitudinal Preregistered Qualitative Peer reviewed |
|---|---|
| Sample size | 706,891 |
| Population | U.S. respondents to the National Survey on Drug Use and Health (2002–2019) |
| Intervention | Psilocybin use |
| Topics | Addiction Psilocybin |
| Keywords | Psychedelics Opioids Racial disparities Public health |
| Citations | 2 |
| Key findings | Race and ethnicity significantly moderated the association between psilocybin use and lowered odds of opioid use disorder, with significant associations found only for White and Hispanic participants. |
Abstract
Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race/ethnicity on this association.
Objective: To assess the impact of race and ethnicity on the association between psilocybin use and lowered odds of OUD using data from the National Survey on Drug Use and Health (2002–2019) (N = 706,891).
Method: I used survey-weighted multivariable logistic regression to test whether race/ethnicity moderates the association between psilocybin use and lowered odds of OUD. Subsequently, I stratified my sample by race and ethnicity and assessed the associations between psilocybin and OUD for individual racial and ethnic groups (White, Black, Indigenous, Asian, Multiracial, Hispanic). My analysis plan was pre-registered.
Results: Race and ethnicity significantly moderated the association between psilocybin and OUD. Furthermore, when I stratified my sample by race and ethnicity, only White participants and Hispanic participants demonstrated a link between psilocybin and lowered odds of OUD (White aOR: 0.84; Hispanic aOR: 0.68). For Black, Asian, Indigenous, and Multiracial participants, psilocybin did not share a significant association with OUD.
Conclusion: Race and ethnicity moderate the associations between psilocybin and OUD. Future longitudinal, experimental, and qualitative research is needed to better understand the pattern of associations I observed in this study.
Comparable studies
Other cross-sectional and survey studies on psilocybin for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey Online survey respondents | 2020 | Cross-sectional survey | |
| User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study Users of hallucinogenic drugs who completed a web-based questionnaire | 2010 | Cross-sectional survey | n = 600 |
| Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample U.S. respondents to the National Survey on Drug Use and Health (2015–2019) | 2022 | Cross-sectional analysis of survey data | n = 214,505 |
| Increased use of illicit drugs in a Dutch cluster headache population People with cluster headache in the Netherlands | 2018 | Cross-sectional study | n = 756 |
| Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample Norwegian adults who have had a memorable experience after taking a classic psychedelic... | 2023 | Cross-sectional survey | n = 770 |
Citations in the library
Cited by 2
- Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA SAIMSARA Journal June 15, 2026
- Exploring the potential psychological predictors associated with changes in depression, anxiety, and well-being following naturalistic psychedelic use. Journal of Psychiatric Research November 1, 2025
Cites 31
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder JAMA Psychiatry August 24, 2022
- Psychedelics and the essential importance of context. Journal of Psychopharmacology February 15, 2018
- Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review Frontiers in Psychiatry July 12, 2022
and 26 more in the library